Healthcare Costs Across Diabetic Kidney Disease Stages: A Veterans Affairs Study

IF 3.2 Q1 UROLOGY & NEPHROLOGY Kidney Medicine Pub Date : 2024-07-18 DOI:10.1016/j.xkme.2024.100873
Kibum Kim , Jacob Crook , Chao-Chin Lu , Heather Nyman , Jyotirmoy Sarker , Richard Nelson , Joanne LaFleur
{"title":"Healthcare Costs Across Diabetic Kidney Disease Stages: A Veterans Affairs Study","authors":"Kibum Kim ,&nbsp;Jacob Crook ,&nbsp;Chao-Chin Lu ,&nbsp;Heather Nyman ,&nbsp;Jyotirmoy Sarker ,&nbsp;Richard Nelson ,&nbsp;Joanne LaFleur","doi":"10.1016/j.xkme.2024.100873","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>In the United States, diabetic kidney disease (DKD) affects about one-third of individuals with type 2 diabetes, causing significant economic burdens on the health care system and affecting patients’ quality of life.</p></div><div><h3>Objective</h3><p>The aim of the study was to quantify the burden of care in patients at different stages of DKD and to monitor shifts in healthcare costs throughout these stages.</p></div><div><h3>Methods</h3><p>This study used data from the Veterans Affairs National database, focusing on US veterans diagnosed with DKD between January 2016 and March 2022. Aggregated all-cause health care costs per month were summarized using descriptive statistics. We used a generalized linear model to calculate the cost of DKD patent care based on the stages, dialysis phase, and kidney replacement therapy.</p></div><div><h3>Results</h3><p>The cohort of 685,288 patients with DKD was predominantly male (96.51%), White (74.42%), and non-Hispanic (93.54%). The mean (SD) per-patient per-month costs were $1,597 ($3,178), $1,772 ($4,269), $2,857 ($13,072), $3,722 ($12,134), $5,505 ($14,639), and $6,999 ($16,901) for stages 1, 2, 3a, 3b, 4 and 5 respectively. The average monthly expenditure for patients receiving long-term dialysis was $12,299. Costs peaked sharply during the first month of kidney replacement therapy at $38,359 but subsequently decreased to $6,636 after 1 year.</p></div><div><h3>Conclusions</h3><p>The economic implications of DKD are profound, emphasizing the need for efficient early detection and disease management strategies. Preventing patients from progressing to advanced DKD stage will minimize the economic repercussions of DKD and will assist health care systems in optimizing resource allocation.</p></div><div><h3>Plain-Language Summary</h3><p>Diabetic kidney disease (DKD) places a substantial burden on health care systems in the United States. In part of our effort to close the knowledge gap around the disease burden, care cost analysis for the patients with DKD was performed for US veterans. Along with stage progression, overall care costs per-patient per-month drastically increases from $1,597 (stage 1) to $6,999 (stage 5). Monthly costs exceeded $10,000 once veterans started to receive long-term dialysis. The quantitative summary will help health care systems efficiently allocate resources across various disease sectors.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000840/pdfft?md5=4c53ed228f9294694e8b1f593960e3ca&pid=1-s2.0-S2590059524000840-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590059524000840","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

In the United States, diabetic kidney disease (DKD) affects about one-third of individuals with type 2 diabetes, causing significant economic burdens on the health care system and affecting patients’ quality of life.

Objective

The aim of the study was to quantify the burden of care in patients at different stages of DKD and to monitor shifts in healthcare costs throughout these stages.

Methods

This study used data from the Veterans Affairs National database, focusing on US veterans diagnosed with DKD between January 2016 and March 2022. Aggregated all-cause health care costs per month were summarized using descriptive statistics. We used a generalized linear model to calculate the cost of DKD patent care based on the stages, dialysis phase, and kidney replacement therapy.

Results

The cohort of 685,288 patients with DKD was predominantly male (96.51%), White (74.42%), and non-Hispanic (93.54%). The mean (SD) per-patient per-month costs were $1,597 ($3,178), $1,772 ($4,269), $2,857 ($13,072), $3,722 ($12,134), $5,505 ($14,639), and $6,999 ($16,901) for stages 1, 2, 3a, 3b, 4 and 5 respectively. The average monthly expenditure for patients receiving long-term dialysis was $12,299. Costs peaked sharply during the first month of kidney replacement therapy at $38,359 but subsequently decreased to $6,636 after 1 year.

Conclusions

The economic implications of DKD are profound, emphasizing the need for efficient early detection and disease management strategies. Preventing patients from progressing to advanced DKD stage will minimize the economic repercussions of DKD and will assist health care systems in optimizing resource allocation.

Plain-Language Summary

Diabetic kidney disease (DKD) places a substantial burden on health care systems in the United States. In part of our effort to close the knowledge gap around the disease burden, care cost analysis for the patients with DKD was performed for US veterans. Along with stage progression, overall care costs per-patient per-month drastically increases from $1,597 (stage 1) to $6,999 (stage 5). Monthly costs exceeded $10,000 once veterans started to receive long-term dialysis. The quantitative summary will help health care systems efficiently allocate resources across various disease sectors.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
糖尿病肾病各阶段的医疗费用:退伍军人事务研究
背景在美国,糖尿病肾病(DKD)影响着约三分之一的 2 型糖尿病患者,给医疗保健系统造成了巨大的经济负担,并影响着患者的生活质量。方法本研究使用退伍军人事务国家数据库中的数据,重点关注 2016 年 1 月至 2022 年 3 月期间确诊患有 DKD 的美国退伍军人。我们使用描述性统计汇总了每月全因医疗费用。我们使用广义线性模型计算了基于分期、透析阶段和肾脏替代疗法的 DKD 专利医疗成本。结果685,288 名 DKD 患者队列中主要为男性(96.51%)、白人(74.42%)和非西班牙裔(93.54%)。1 期、2 期、3a 期、3b 期、4 期和 5 期患者每人每月的平均费用(标度)分别为 1,597 美元(3,178 美元)、1,772 美元(4,269 美元)、2,857 美元(13,072 美元)、3,722 美元(12,134 美元)、5,505 美元(14,639 美元)和 6,999 美元(16,901 美元)。长期透析患者的月平均费用为 12,299 美元。在接受肾脏替代治疗的第一个月,费用急剧攀升至 38,359 美元,但随后在一年后降至 6,636 美元。防止患者发展到 DKD 晚期将最大限度地减少 DKD 对经济的影响,并有助于医疗保健系统优化资源分配。为了填补有关疾病负担的知识空白,我们对美国退伍军人中的 DKD 患者进行了护理成本分析。随着阶段的进展,每位患者每月的总体护理成本从 1597 美元(第 1 阶段)急剧增加到 6999 美元(第 5 阶段)。一旦退伍军人开始接受长期透析,每月费用就会超过 10,000 美元。量化总结将有助于医疗保健系统在不同疾病领域有效地分配资源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Kidney Medicine
Kidney Medicine Medicine-Internal Medicine
CiteScore
4.80
自引率
5.10%
发文量
176
审稿时长
12 weeks
期刊最新文献
Living Donor Candidates’ Self-reported Health and Health Perceptions and Completion of Donor Evaluation: A Cohort Study Undetected Air Embolism During Hemodialysis from a Defective Central Venous Catheter Causing Intradialytic Cardiac Arrest: An Imaging Teaching Case The Surprise Question in Hemodialysis, Frailty, Nutrition, Patient-reported Quality of Life, and All-Cause Mortality: The Osaka Dialysis Complication Study (ODCS) Antihypertensive Treatment Patterns in CKD Stages 3 and 4: The CKD-REIN Cohort Study Advanced CKD of Uncertain Etiology Among Children in Guatemala: Genetic and Clinical Characteristics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1